Lineage Cell Therapeutics Inc (AMEX:LCTX) has a beta value of 1.18 and has seen 8.64 million shares traded in the last trading session. The company, currently valued at $114.24M, closed the last trade at $0.61 per share which meant it gained $0.04 on the day or 5.42% during that session. The LCTX stock price is -163.93% off its 52-week high price of $1.61 and 18.03% above the 52-week low of $0.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.9 million shares traded. The 3-month trading volume is 945.22K shares.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Sporting 5.42% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the LCTX stock price touched $0.61 or saw a rise of 17.23%. Year-to-date, Lineage Cell Therapeutics Inc shares have moved -44.50%, while the 5-day performance has seen it change -33.02%. Over the past 30 days, the shares of Lineage Cell Therapeutics Inc (AMEX:LCTX) have changed -31.25%. Short interest in the company has seen 15.94 million shares shorted with days to cover at 35.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Figures show that Lineage Cell Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -34.95% over the past 6 months, with this year growth rate of -8.33%, compared to 17.90% for the industry. Revenue growth from the last financial year stood is estimated to be -11.01%.
7 analysts offering their estimates for the company have set an average revenue estimate of 1.66M for the current quarter. 4 have an estimated revenue figure of 1.02M for the next ending quarter. Year-ago sales stood 2.12M and 1.44M respectively for this quarter and the next, and analysts expect sales will shrink by -21.78% for the current quarter and -11.01% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.25% over the past 5 years.
LCTX Dividends
Lineage Cell Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Insiders own 0.44% of the company shares, while shares held by institutions stand at 50.56% with a share float percentage of 50.79%. Investors are also buoyed by the number of investors in a company, with Lineage Cell Therapeutics Inc having a total of 143.0 institutions that hold shares in the company. The top two institutional holders are BROADWOOD CAPITAL INC with over 41.67 million shares worth more than $41.55 million. As of 2024-06-30, BROADWOOD CAPITAL INC held 22.7798% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 9.56 million shares as of 2024-06-30. The firm’s total holdings are worth over $9.53 million and represent 5.2264% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Jun 30, 2024 , the former fund manager holds about 2.34% shares in the company for having 4.42 shares of worth $2.67 million while later fund manager owns 3.72 shares of worth $2.25 million as of Sep 30, 2024 , which makes it owner of about 1.97% of company’s outstanding stock.
